BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has a portfolio of commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. Galafold (migalastat) is its oral treatment for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), is a two-component therapy for Pompe disease. Its portfolio also includes ALE1, an oral small molecule for the potential treatment of hypophosphatasia (HPP), a rare genetic bone disease caused by mutations in the ALPL gene.
Back to dashboard
Company Information
About this company
Key people
Ian T. Clark
Independent Chairman of the Board
James H. Sabry
Chief Business Officer
Elizabeth Mckey Anderson
Independent Director
Barbara W. Bodem
Independent Director
Athena M. Countouriotis
Independent Director
Willard H. Dere
Independent Director
Alexander Hardy
President, Chief Executive Officer, Director
Brian R. Mueller
Chief Financial Officer, Executive Vice President
C. Greg Guyer
Executive Vice President and Chief Technical Officer
G. Eric Davis
Executive Vice President, Secretary, Chief Legal Officer
Arpit Dave
Executive Vice President, Chief Digital and Information Officer
Gregory R Friberg
Executive Vice President, Chief Research and Development Officer
Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Rashmi Ramchandani
Chief Accounting Officer, Vice President
Click to see more
Key facts
- Shares in issue193.57m
- EPICBMRN
- ISINUS09061G1013
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$10.58bn
- Employees3,221
- ExchangeNASDAQ
- IndexS&P 400 Mid Cap, TR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.